HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

The European Parliament's Committee on the Environment, Public Health and Food Safety has voted to strengthen the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) legislation during a meeting Oct. 10. The vote passed with 42 members in favor, 12 opposed and six abstentions. Amendments to the legislation include establishing a quality mark for REACH-compliant products, increased focus on alternatives to animal testing and a requirement for substituting compounds deemed "the most hazardous substances" with less toxic ingredients. REACH will undergo a deliberation in the near term before the entire Parliament before it is reviewed by the EU Council of Ministers. Slated to go into effect in the first quarter of next year, REACH requires importers and manufacturers of more than one ton of chemical per year to register with a European chemicals agency. A proposal for the legislation was overhauled in 2003 to reduce burdens on downstream users (1"The Rose Sheet" Nov. 3, 2003, p. 11)...

You may also be interested in...

EU Chemical Plan Overhaul Exempts Polymers, Reduces Burden Downstream

The European Commission's 1chemical testing proposal released Oct. 29 includes provisions to exempt certain polymers and reduce the burden on downstream users in an effort to address industry concerns

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts